A pilot investigation of clinical effects of PM-33, a new anti-anxiety agent.
D000704:Analysis of Variance; D000814:Aniline Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000503:physiopathology; D001008:Anxiety Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004123:Dimethylamines / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D004569:Electroencephalography; D005019:Ethyl Ethers / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008950:MMPI; D008298:Maleates / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D013997:Time Factors
D000814:Aniline Compounds; D014151:Anti-Anxiety Agents; D004123:Dimethylamines; D005019:Ethyl Ethers; D008298:Maleates; C006028:PM-33